---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-262950"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2026-06-09T11:03:35+00:00"
generated_at: "2026-06-09T11:05:13.797449+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# GSK to acquire Nuvalent for $124/share (~$10.6B); assets under FDA review for 2026 approval

## Summary
- All-share tender offer at $124.00 per share; aggregate equity value ~$10.6B; net cash investment ~$9.4B.
- 40% premium to last closing price; 26% premium to 30-day VWAP; no financing condition.
- Deal includes late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib; FDA decisions due Sept/Nov 2026.
- Supporting stockholders (~28% of Class A shares) have agreed to tender; termination fee $350.5M.
- Transaction expected to close Q3 2026; GSK expects accretion to operating profit in 2027, EPS in 2029.

## SEC filing metadata
- accession: 0001193125-26-262950
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2026-06-09T11:03:35+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000119312526262950/0001193125-26-262950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000119312526262950/d137459d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-262950
- JSON: https://secwatch.observer/filing/0001193125-26-262950.json
- Plain text: https://secwatch.observer/filing/0001193125-26-262950.txt

## Key facts
- Material Agreements
  Nuvalent, Inc. entered into Agreement and Plan of Merger with GlaxoSmithKline LLC, Harmony Row Acquisition Co., and GSK plc valued at $124.00 per Share (effective 2026-06-09).
  - Action: entry
  - Agreement: merger
  - Counterparty: GlaxoSmithKline LLC, Harmony Row Acquisition Co., and GSK plc
  - Value: $124.00 per Share
  - Effective: 2026-06-09
  source text: On June 9, 2026, Nuvalent, Inc., a Delaware corporation (the “ Company ” or “ Nuvalent ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with GlaxoSmithKline LLC, a Delaware limited liability company (“ Parent ”), Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (“ Purchaser ”) and, solely for purposes of Section 9.14 thereof, GSK plc, a public limited company organized under the laws of England and Wales (“ Ultimate Parent ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1861560/000119312526262950/0001193125-26-262950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.